• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ipsen S.A. (OP: IPSEF )

    125.37 UNCHANGED
    Last Price Updated: 11:08 AM EDT, Oct 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Ipsen S.A.

    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
    Via Benzinga
    France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
    Via Benzinga
    Why Merrimack Shares Are Surging Over 200% Today?
    Via Benzinga
    Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
    Via Benzinga
    Why Is Epizyme (EPZM) Stock Up 75% Today?
    EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen. 
    Via InvestorPlace
    Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
    Ipsen SA (OTC: IPSEY) has 
    Via Benzinga
    Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
    Via Benzinga
    EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
    Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have  
    Via Benzinga
    Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
    Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... 
    Via Benzinga
    Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
    Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... 
    Via Benzinga
    Ipsen Stock Declines After Pulling Rare Disease Application
    Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... 
    Via Benzinga
    Exposures Product Safety
    Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
    Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as... 
    Via Benzinga
    Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
    Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,... 
    Via Benzinga
    Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
    Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.